ARTICLE | Clinical News
Progenics down on MNTX news
August 10, 2004 7:00 AM UTC
PGNX was off $2.08 (18%) to $9.18 on Tuesday after disclosing that it now expects data from a second Phase III trial of its methylnaltrexone (MNTX) to treat opioid-induced constipation in patients wit...